Mode
Text Size
Log in / Sign up

Serum lactate levels associated with 1.40 odds of unfavorable neurobehavioral outcome in pediatric cardiac arrestSerum Lactate Levels May Help Predict Outcomes After Cardiac Arrest

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher serum lactate levels are associated with increased odds of poor neurobehavioral outcomes in pediatric OHCA.

This secondary analysis of an RCT included 213 pediatric patients following out-of-hospital cardiac arrest (OHCA). The study evaluated serum lactate as a potential biomarker for neuroprognostication and mortality prediction over a 12-month follow-up period.

Patients with unfavorable neurobehavioral outcomes at 12-months had a median lactate of 7.8 compared to 3.1 in those with favorable outcomes (95% CI [3.7-5.9]). Additionally, patients who died in the hospital had a median lactate of 8.6 compared to 3.6 for survivors (95% CI [4.0-6.1]). The analysis found an odds ratio of 1.40 for the primary unfavorable outcome for every 1 mmol/L increase in lactate (95% CI [1.17, 1.69]).

Safety and tolerability data were not reported. The study is a secondary analysis, and the results are based on AUROC and odds ratios. While lactate shows potential as an adjunct for early neuroprognostication and mortality prediction, it should not be used as a standalone diagnostic tool. The findings indicate an association rather than a causal link between lactate levels and neurological outcomes.

How this fits prior evidence

This finding addresses a gap in identifying early biomarkers for neuroprognostication in pediatric cardiac arrest. While previous evidence noted that bystander CPR increases 30-day survival odds by 50% and that triple therapy (Vasopressin, steroids, and epinephrine) improves ROSC, these findings do not provide specific prognostic indicators for long-term neurological outcomes. This study provides a specific metric for lactate as a potential adjunct for predicting 12-month outcomes.

Researchers analyzed data from 213 children who experienced out-of-hospital cardiac arrest. The study looked at serum lactate levels, which is a substance that builds up in the blood when the body is under stress. They compared these levels to the children's health outcomes one year later.

The results showed that children with higher median lactate levels (7.8) were more likely to have unfavorable neurobehavioral outcomes compared to those with lower levels (3.1). Additionally, children who died in the hospital had significantly higher median lactate levels (8.6) than those who survived (3.6). For every 1 mmol/L increase in lactate, the odds of a poor outcome at 12 months increased by 1.40.

It is important to note that this was a secondary analysis of a trial, and the results show a link rather than a direct cause. Lactate is not a standalone tool for diagnosis. Because these findings are based on a specific study group, you should speak with a medical professional to understand how these markers apply to specific patient care.

What this means for you:
Higher lactate levels in children after cardiac arrest are linked to higher risks of death and poor neurological outcomes.

Common questions

What does a high lactate level mean after a cardiac arrest?

In this study of 213 children, higher serum lactate levels were linked to poorer outcomes. Children with a median lactate of 7.8 had unfavorable neurobehavioral outcomes at 12 months, while those with a median of 3.1 had better outcomes. Higher levels were also associated with a higher risk of death in the hospital.

How does lactate help predict a child's recovery?

The study found that for every 1 mmol/L increase in lactate, the odds of an unfavorable outcome at 12 months increased by 1.40. This suggests that lactate levels may serve as a helpful extra tool for doctors to predict potential neurological issues or mortality after a cardiac arrest.

Is lactate a definitive way to tell if a child will recover?

No, lactate is not a standalone diagnostic tool. This study shows a link between lactate and outcomes, but it does not prove that lactate causes these outcomes. Because this was a secondary analysis, the results should be used as one piece of information rather than a final prediction.

Study Details

Study typeRct
Sample sizen = 213
EvidenceLevel 2
Follow-up12.0 mo
PublishedSep 2026
View Original Abstract ↓
BACKGROUND: Neuroprognostication after pediatric out-of-hospital cardiac arrest (OHCA) is challenging. Serum lactate has potential as an adjunct biomarker. We examined the association of lactate measurements with 12-month neurobehavioral outcomes and hospital mortality in a secondary analysis of the Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-of-Hospital (THAPCA-OH) trial. METHODS: Study participants with at least one lactate measurement (mmol/L) within 24-h of return of spontaneous circulation (ROSC) were included. The primary outcome was unfavorable neurobehavioral functioning or death at 12-months. Univariable, multivariable and area under the receiver operator characteristic curve (AUROC) analyses were performed at four timepoints: first lactate within 6 or 12-h, and peak lactate within 12 or 24-h of ROSC. RESULTS: The primary analysis included 213 patients, 82% of which had a primary unfavorable outcome. AUROCs showed strong association of lactate with all outcomes and were similar between timepoints, thus we reported the analyses of first lactate within 6 h of ROSC. Median lactate measurements were higher among those with primary unfavorable versus favorable 12-month outcome (7.8 versus 3.1, difference [95%CI]: 4.8[3.7-5.9]) and those who died in the hospital versus survivors (8.6 versus 3.6, difference [95%CI]: 5.1[4.0-6.1]). For each lactate increase of 1 mmol/L, odds (95%CI) of primary unfavorable outcome at 12-months increased 1.40 (1.17, 1.69). CONCLUSION: Among subjects enrolled in the THAPCA-OH trial, higher lactates within 6-h of ROSC were associated with unfavorable outcome at one year. Lactate has potential as an adjunct for early neuroprognostication and mortality prediction.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.